Scinovex
article Open AccessTop 1% cited

Guidelines for Treatment of Candidiasis

Clinical Infectious Diseases · 2004 · Vol. 38(2) · pp. 161–189
Peter G. PappasJohn RexJack D. SobelScott G. FillerWilliam E. DismukesThomas J. WalshJohn E. Edwards

Abstract

Good evidence to support a recommendation against use Quality of evidence 1 Evidence from 1 properly randomized, controlled trial 2 Evidence from 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from 11 center); from multiple time-series; or from dramatic results from uncontrolled experiments 3 Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees

MeSH terms

Antifungal AgentsCandidaCandidiasisHumansMicrobial Sensitivity Tests

Funding

  • National Cancer Institute
Citations
1,443
FWCI
73.33
field-weighted impact
References
328
Percentile
100%
vs. same field & year
Citations per year
References
Fluconazole
Drugs · 1990 · 659 citations
Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations
American Journal of Obstetrics and Gynecology · 1998 · 699 citations
Current and Emerging Azole Antifungal Agents
Clinical Microbiology Reviews · 1999 · 1,115 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.